← Leaderboards
Alfredo G Torres
University Of Texas Med Br Galveston
$6,969,634
Attributed
$6,969,634
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2009–22$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,969,634 · 6
By mechanism
R01$4,023,212 · 2
U54$1,656,672 · 1
R21$1,289,750 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenInfectionPreventProteinsInnovationOrganismInsightPropertyIn VivoBiothreatCategoriesVirulence FactorsPathogenic BacteriaPathogenic Escherichia ColiEscherichia Coli EhecEscherichia ColiEscherichia Coli InfectionsPlayHuman DiseaseDiarrheaImmune ResponseHemolytic-Uremic SyndromeAntigensBase
Grant awards (20)
Developing effective nanovaccines against pathogenic Escherichia coli$197,500
R21 · FY2022 · AI · contact PI
Developing effective nanovaccines against pathogenic Escherichia coli$237,000
R21 · FY2021 · AI · contact PI
Defining the role of toxin-antitoxin systems in persistence of Burkholderia pseudomallei$197,500
R21 · FY2021 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$433,532
R01 · FY2020 · AI · contact PI
Defining the role of toxin-antitoxin systems in persistence of Burkholderia pseudomallei$237,000
R21 · FY2020 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$457,812
R01 · FY2019 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$455,661
R01 · FY2018 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$22,099
R01 · FY2018 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$387,500
R01 · FY2017 · AI · contact PI
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections$387,500
R01 · FY2016 · AI · contact PI
Vaccine Development for Burkholderia amllei and B. pseudomallei$690,511
U54 · FY2013 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$349,163
R01 · FY2013 · AI · contact PI
Vaccine Development for Burkholderia amllei and B. pseudomallei$966,161
U54 · FY2012 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$371,450
R01 · FY2012 · AI · contact PI
E. coli O157: H7 Vaccine Development$191,250
R21 · FY2012 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$371,450
R01 · FY2011 · AI · contact PI
E. coli O157: H7 Vaccine Development$229,500
R21 · FY2011 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$375,202
R01 · FY2010 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$391,742
R01 · FY2009 · AI · contact PI
Long Polar Fimbriae of Attaching and Effacing Escherichia coli$20,101
R01 · FY2009 · AI · contact PI